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On 17 May 2013, the World Health Organization’s (WHO)
Strategic Advisory Group of Experts (SAGE) on Immunization
announced a paradigm change regarding yellow fever (YF)
vaccination policy, stating that there was no need for
revaccination of immune-competent individuals 10 years after
an initial vaccination [1]. Supplies of yellow fever vaccine are
regularly overstretched. Reduction in the need for revaccina-
tion would increase the amount of vaccine available; therefore,
the importance of this policy change should not be underes-
timated. However, there are important issues that render the
basis for this bold move questionable.
The actual policy change hinges on information compiled in
a comprehensive background paper [2] on long-term immu-
nogenicity of the 17D YF vaccine. It includes a to date
unpublished systematic review by Gotuzzo and colleagues
postulating that evidence for lifelong immunity in healthy
subjects was overwhelming (although the data referred to in
support of this notion [2] showed that conﬁdence in the
estimate of the effect is limited). Further unpublished data
were taken into account, conﬁrming the risk of yellow fever
vaccine-related viscerotropic disease following vaccination of
elderly individuals, and recent research by Rafferty and
colleagues into the role of cellular and innate immunity in
the response to vaccination [E. Rafferty, unpublished data].
The revaccination policy was previously examined in 2003. It
was stated at that time that the recommendations in Interna-
tional Health Regulations (IHR) since 1965 were based on
limited evidence, which at that time was interpreted with
caution, thus allowing for a safety margin of error [3]. To that
end, the new recommendation announced on 17 May 2013 is
remarkable because since 1965 few data on the duration of
immunity have been published, and these provide only a limited
base for this policy change.
As it stands, we question the conclusion that lifelong
protection is sufﬁciently supported by the evidence presented
in the background paper [2]. We identify the following
remaining issues, which in our view ought to be considered.
 Currently, the presence of neutralizing antibodies
against 17D-YFV is ofﬁcially considered the best available
proxy of protection after yellow fever vaccination. How-
ever, the use of different techniques and PRNT assay cut-off
values to deﬁne protection hampers uniform interpretation
of the study results (table 1 in reference [2]). With the
PRNT, the capacity of a given dilution of immune serum to
prevent plaque formation by 17D-YF virus in a cell culture
in comparison to non-immune serum is expressed as
percentage neutralization. In the cited studies, this percent-
age varies from 50% to 90% in serum dilutions ranging from
1:2 to >1:40. We strongly advocate the use of a universally
accepted cut-off value (preferably expressed in international
units using a reference serum) to deﬁne protection in future
studies.
 The small number of documented cases of break-through
infections might be an underestimate, as post-vaccination
surveillance in most endemic areas is poor. With regard to
outbreaks of yellow fever that occurred in Nigeria during
the 1980s, it was found, in a limited survey, that almost all
unvaccinated individuals aged 20 years and older had
neutralizing antibodies. This implies that ongoing endemic
transmission boosted the immunological memory in previ-
ously immunized individuals; however, there is the problem
of ﬂavivirus antibodies cross-reacting with ﬂaviviruses other
than the infective agent.
 The recommendation for revaccination predominantly
applies to travellers. The lack of documented vaccine failures
in travellers who have been vaccinated against yellow fever
virus can be explained by the rarity of yellow fever in
travellers in general and does not exclude the possibility of
waning immunity.
 Some studies show long-term immunity, but not in all
individuals. Percentages range from 70% to 96% (table 1 in
reference [2]). So, after >20 years following vaccination, 4–
30% of vaccinated individuals do not have neutralizing
antibodies.
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 We acknowledge that immune memory of yellow fever
vaccine may persist even in the absence of neutralizing
antibodies, but we doubt that (given the short incubation
period) this will sufﬁce to regularly protect all individuals
against yellow fever virus infection.
We agree with the statement of the working group that
many uncertainties remain. These knowledge gaps reduce
conﬁdence in the recommendation to immediately completely
abolish revaccination. A more prudent approach would be to
increase the revaccination interval from 10 to 20 years, and to
deﬁne a cut-off percentage of the vaccine population that
should be protected in order to deﬁne acceptable efﬁcacy. At
the same time, improved post-vaccination surveillance on a
global scale should be implemented (although we acknowledge
the practical difﬁculties), and studies to gain more insight into
the presence of (cellular) immunity in those individuals not
exhibiting neutralizing antibodies should be conducted. In
practical terms, we advocate the use of unequivocal PRNT
cut-off values to deﬁne protection expressed in international
units by using a reference serum, and to deﬁne the lower level
of seroprotection that is deemed acceptable in various
populations that are at risk of contracting yellow fever.
In conclusion, SAGE favours a quantum leap in YF revac-
cination policy towards non-revaccination of healthy individ-
uals, which stands in stark contrast to the remaining gaps in
our knowledge. At the same time, they justiﬁably remain much
more cautious about the safety of the vaccine and the duration
of protection in selected populations with diminished immu-
nity. We believe the best way forward at this moment is to
moderately extend the revaccination interval from 10 to
20 years, whilst initiating global post-vaccination surveillance
and fostering research into the kinetics and mechanisms of
protection.
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